The results demonstrated that high expression of CAMK2N1 was strongly linked to PD1, PD-L1, and CTLA-4 in GC, suggesting that targeting CAMK2N1 might increase the efficacy of immunotherapy in GC. The gene discussed is CTLA4; the disease is gastric cancer.